Literature DB >> 3133342

The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients.

S Yazawa1, T Asao, H Izawa, Y Miyamoto, K L Matta.   

Abstract

Eighteen cancer patients showed high levels of CA19-9 in sera, even though the blood-group phenotypes of their red blood cells were Le(a-b-). Seven of these patients (group I) were determined as Le(a-b-) from both red blood cells and saliva consistently, whereas eleven other patients (group II) secreted either Le(a) or Le(b) antigen in saliva and showed the expression of incompatible Lewis blood-group antigens. GDP-fucose: N-acetyl-glucosaminide alpha(1----4)-L-fucosyltransferase was demonstrated to be present in salivas from both group I and group II. These results suggest that a cancer-associated alteration of Lewis blood-group antigen expression occurs in cancer patients.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3133342      PMCID： PMC5917498          DOI： 10.1111/j.1349-7006.1988.tb01624.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


N‐acetylneuraminic acid o‐galactose L‐fucose N‐acetyl‐o‐glucosamine radiometric immunoassay benzyl bovine serum albumin N‐2.hydroxyethylpipera‐zinc‐N′‐2‐ethanesulfonic acid
  23 in total

1.  Cancer-associated alterations of blood group antigen expression in human colorectal polyps.

Authors:  S H Itzkowitz; M Yuan; L D Ferrell; A Palekar; Y S Kim
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

2.  Isolation and purification of Lewis blood-group active glycosphingolipids from the plasma of human O Leb individuals.

Authors:  P Hanfland
Journal:  Eur J Biochem       Date:  1978-06-01

3.  Neoexpression of ABH and Lewis blood group antigens in human hepatocellular carcinomas.

Authors:  Y Okada; T Arima; K Togawa; H Nagashima; K Jinno; S Moriwaki; T Kunitomo; J Thurin; H Koprowski
Journal:  J Natl Cancer Inst       Date:  1987-01       Impact factor: 13.506

4.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

5.  Use of N-acetyl-2'-O-methyllactosamine as a specific acceptor for the determination of alpha-L-(1----3)-fucosyltransferase in human serum.

Authors:  R Madiyalakan; S Yazawa; S A Abbas; J J Barlow; K L Matta
Journal:  Anal Biochem       Date:  1986-01       Impact factor: 3.365

6.  Distribution of blood group antigens A, B, H, Lewisa, and Lewisb in human normal, fetal, and malignant colonic tissue.

Authors:  M Yuan; S H Itzkowitz; A Palekar; A M Shamsuddin; P C Phelps; B F Trump; Y S Kim
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

7.  CA 19-9 and pancreatic adenocarcinoma.

Authors:  F Safi; H G Beger; R Bittner; M Büchler; W Krautzberger
Journal:  Cancer       Date:  1986-02-15       Impact factor: 6.860

8.  Enzymatic synthesis of blood-group Lewis-specific glycolipids.

Authors:  R Prohaska; H Schenkel-Brunner; H Tuppy
Journal:  Eur J Biochem       Date:  1978-03

9.  Elevated activities of blood group Le gene dependent alpha(1----3)-L-fucosyltransferase in human saliva of Lewis negative patients with epithelial ovarian cancer.

Authors:  S Yazawa; R Madiyalakan; M S Piver; K L Matta
Journal:  Cancer Lett       Date:  1986-08       Impact factor: 8.679

10.  Normal salivary mucin contains the gastrointestinal cancer-associated antigen detected by monoclonal antibody 19-9 in the serum mucin of patients.

Authors:  M Brockhaus; M Wysocka; J L Magnani; Z Steplewski; H Koprowski; V Ginsburg
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144
View more
  7 in total

1.  Associated expression of α2,3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer.

Authors:  Takaharu Fukasawa; Takayuki Asao; Hayato Yamauchi; Munenori Ide; Yuichi Tabe; Takaaki Fujii; Satoru Yamaguchi; Soichi Tsutsumi; Shin Yazawa; Hiroyuki Kuwano
Journal:  Surg Today       Date:  2012-03-08       Impact factor: 2.549

2.  Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.

Authors:  P Masson; B Pålsson; A Andrén-Sandberg
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

3.  Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.

Authors:  S Kawa; H Oguchi; T Kobayashi; M Tokoo; S Furuta; M Kanai; T Homma
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

4.  Frequency and mechanism of Lewis antigen expression in human urinary bladder and colon carcinoma patients.

Authors:  N C Langkilde; H Wolf; P Meldgård; T F Orntoft
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

5.  Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.

Authors:  Shin Yazawa; Ryo Takahashi; Takehiko Yokobori; Rie Sano; Akira Mogi; Abby R Saniabadi; Hiroyuki Kuwano; Takayuki Asao
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

6.  Aberrant alpha 1-->2fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Leb and Y antigens in colorectal tumors.

Authors:  S Yazawa; J Nakamura; T Asao; Y Nagamachi; M Sagi; K L Matta; T Tachikawa; M Akamatsu
Journal:  Jpn J Cancer Res       Date:  1993-09

7.  Development and characterization of a novel anti-fucosylated antigen monoclonal antibody YB-2 and its usefulness in the immunohistochemical diagnosis of colorectal cancer.

Authors:  S Yazawa; S Akamatsu; T Tachikawa; H Naito; J Nakamura; T Asao; Y Nagamachi; T Nakajima; S Shin; D Chia
Journal:  Jpn J Cancer Res       Date:  1993-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.